TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: AUC of warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under The Concentration Versus Time Curve From Zero To Infinity (AUC[0-∞])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Blood Volume in Part 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Bleeding Duration in Part 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Prothrombin Time (PT) in Part 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With Incremental IF/A Scores >2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average variation in pain at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average variation in pain in motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Analog pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental shuttle walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Laboratory Abnormalities Meeting the Criteria for Potential Clinical Concern
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Suicidal Ideation or Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Mexameter score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of organ failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients completing the study protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Smoke toxin excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Analyte Concentration versus Time Curve (AUC72h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Analyte Concentration versus Time Curve (AUC240h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vitamin D concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Heart Rate in beats/min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean R-R interval in milliseconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Isotope Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Experiencing at Least One Asthma Exacerbation
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of convulsive seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Ability to complete the outlined course of therapy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Ability to harvest, expand, and reinfuse autologous T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Degree of Change in 17-item Hamilton Depression Rating Scale (HAM-D 17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: In-hospital major adverse cardiac events (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in baseline flow-mediated vasodilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median duration of cabozantinib treatment (months)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: change in total plasma homocysteine (tHcy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence rate of IBD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence rate of IBD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Pain Interference
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sought treatment for alcohol use disorder
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Antibody titers against Coxiella burnetii
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of major complications
Endpoint domain: Adverse events/effects
Primary endpoint: number of targets reached
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose Length Product (DLP)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 18F-PSMA PET/CT imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in resting myocardial PCr/ATP ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of functional decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of high blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 3-year Prostate-specific Antigen Progression-free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Total Hip Replacement Self-efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self-care competence Scale
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Spouse satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline fluid control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in symptom severity in patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline quality of life in patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: unprotected anal intercourse with a male partner in the past 3 months
Endpoint domain: Adverse events/effects
Primary endpoint: unprotected anal intercourse at last sex with a main male partner
Endpoint domain: Adverse events/effects
Primary endpoint: unprotected anal intercourse at last sex with the most recent non-main male partner
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of Facial Rhytids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline modified Rodnan Skin score (mRSS) of hands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Occurrence Rate of Uveitis Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Annual Incidence Rate of New Uveitis Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neuromuscular response (central activation ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characteristics of gait (stride length, step length, etc.)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualified success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients alive and progression free at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Cmax for a single dose of vandetanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t) for a single dose of vandetanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of Temporomandibular Joint pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WSRS improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sperm cell concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sperm cell motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sperm cell morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal ETEC excretion curve over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total daily fecal output curve over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: recurrence of atrial fibrillation
Endpoint domain: Mortality/survival
Primary endpoint: Mean Ocular Itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Analog Questionnaire (VAQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: subjective cylinder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Troponin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of Participants with local recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety and tolerability of vildagliptin 50 mg bid
Endpoint domain: Adverse events/effects
Primary endpoint: Eradication rate of PPI based therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of hepatocellular carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline on the 2-stage Steady State Plasma Glucose test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline on the radiographic measurement of visceral to subcutaneous (V:S) fat ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline on the magnetic-resonance based measurement of intrahepatic lipid deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency and incidence of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and specificity at AHI threshold value of 15/h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity and specificity at AHI threshold value of 30/h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hand Grip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Plasma Concentration of Antibodies to Pertussis Antigen (1 Week Post-vaccine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Plasma Concentration of Antibodies to Pertussis Antigen (2 Weeks Post-vaccine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Plasma Concentration of C-Reactive Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Number of Muscle Macrophages Per Myofiber (Pre- to Post-acute Exercise)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Muscle Strength After Exercise Training for 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Glucose infusion rate curve (GIR-AUC0-36)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with established diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC0-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in 24-hour Urine Uric Acid Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patency of the vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Residual glomerular filtration rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline in central corneal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in endothelial cell density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in baseline in Rome criteria for functional constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptoms of pelvic floor dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Contrast-agent associated nephrotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of successful tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in minutes per week of moderate-to-vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of LDL-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of adverse events grade 3-4
Endpoint domain: Adverse events/effects
Primary endpoint: Improved Overactive Bladder Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometriosis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in signal intensity in a Region of Interest on MRI scanning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total lung resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of Staff Interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With Major Adverse Cardiovascular Events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with post-operative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Re-occurrence Rate of Skin Tags
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Number of Patients Being Adherent/Non-adherent After the Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the Median IPV Before and After the Intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Outpatient Clinic Nonattendance Rate Before and After the Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Accuracy of staging high-risk primary prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Detection of sites of recurrent prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Tricuspid Annular Plane Systolic Excursion (TAPSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: disease burden evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: risk of gene related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Bispectral Index value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Group B2 participants with resectable tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response rate for Group F patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of neutrophils expressing TLR4 in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patency of the target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Freedom from perioperative death
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from major adverse limb event
Endpoint domain: Adverse events/effects
Primary endpoint: Voluntary activation of upper and lower limb muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cmax of rogaratinib in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-tlast) of rogaratinib in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of rogaratinib in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensive care stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: response rate after one application of DepoCyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in whole-body protein metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline Mental Health at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Mental Wellbeing at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain during the injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of the OSNA Breast Cancer System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required to perform the trial method
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: MoCa test score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of patients with 2 hour pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of bladder and lumbar stimulation technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality of patients with acute ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Functional status of patients with acute ischemic stroke
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: General Neurodevelopmental Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebrospinal fluid biomarkers of degeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Computerised gait analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound measurement of cerebral pulsatility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hydrodynamic characteristics of cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neuronal correlates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time of radiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of hemoglobin level after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sensory characteristics of the pizza
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satiating power of the pizza
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of tidal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of transpulmonary pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Compliance with Choosing Wisely guidelines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Surgical Site Infection at D30
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of Streptococcus pneumoniae antigens in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Detection of Streptococcus pneumoniae DNA in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Consistent contraception
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: ED50 of DEX for sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Liebowitz Social Anxiety Scale (LSAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Brief Fear of Negative Evaluation Scale (BFNE)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Appraisal of Social Concerns Scale (ASC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: volume decrease in relation to interface pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of good functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes